{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T15:53:08Z","timestamp":1794757988148,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Jiangxi Province High-level and High-skilled Leading Talents Training Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04315-3","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:54:45Z","timestamp":1777118085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Overcoming blood-brain barrier and chemoresistance in glioblastoma by Angiopep-2-modified NK cell-derived extracellular vesicles for targeted delivery of temozolomide"],"prefix":"10.1186","volume":"24","author":[{"given":"Jun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yancong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaishuai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"1","key":"4315_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","volume":"9","author":"A Bikfalvi","year":"2023","unstructured":"Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer. 2023;9(1):9\u201327.","journal-title":"Trends Cancer"},{"issue":"7","key":"4315_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329(7):574\u201387.","journal-title":"JAMA"},{"issue":"4","key":"4315_CR3","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1002\/cai2.70018","volume":"4","author":"Y Gong","year":"2025","unstructured":"Gong Y, Lin W, Fang X, Zhang R, Luo M, Wu H, Chu S, Li C, Peng Y, Piao Z, et al. Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions. Cancer Innov. 2025;4(4):e70018.","journal-title":"Cancer Innov"},{"key":"4315_CR4","doi-asserted-by":"crossref","unstructured":"Obrador E, Moreno-Murciano P, Oriol-Caballo M, L\u00f3pez-Blanch R, Pineda B, Guti\u00e9rrez-Arroyo JL, Loras A, Gonzalez-Bonet LG, Martinez-Cadenas C, Estrela JM et al. Glioblastoma Therapy: Past, Present and Future. Int J Mol Sci. 2024;25(5):2529.","DOI":"10.3390\/ijms25052529"},{"issue":"5","key":"4315_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, Gomez C, Bebawy JF, Liu BP, Bouchoux G, et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023;24(5):509\u201322.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4315_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cell.2024.11.002","volume":"188","author":"SK Tetzlaff","year":"2025","unstructured":"Tetzlaff SK, Reyhan E, Layer N, Bengtson CP, Heuer A, Schroers J, Faymonville AJ, Langeroudi AP, Drewa N, Keifert E, et al. Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing. Cell. 2025;188(2):390\u2013e411336.","journal-title":"Cell"},{"issue":"1","key":"4315_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, Prasad S, Wang P, Singh A, Singh G. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10(1):213.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4315_CR8","doi-asserted-by":"publisher","first-page":"188616","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188616.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"4","key":"4315_CR9","first-page":"513","volume":"19","author":"R Ortiz","year":"2021","unstructured":"Ortiz R, Perazzoli G, Cabeza L, Jim\u00e9nez-Luna C, Luque R, Prados J, Melguizo C. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Curr Neuropharmacol. 2021;19(4):513\u201337.","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"4315_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/neuonc\/noab003","volume":"23","author":"S Wu","year":"2021","unstructured":"Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021;23(6):920\u201331.","journal-title":"Neuro Oncol"},{"issue":"1","key":"4315_CR11","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1038\/s41467-020-17717-0","volume":"11","author":"B Oldrini","year":"2020","unstructured":"Oldrini B, Vaquero-Siguero N, Mu Q, Kroon P, Zhang Y, Gal\u00e1n-Ganga M, Bao Z, Wang Z, Liu H, Sa JK, et al. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nat Commun. 2020;11(1):3883.","journal-title":"Nat Commun"},{"issue":"1","key":"4315_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","volume":"24","author":"A Pouyan","year":"2025","unstructured":"Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, Mokhtari K, Shahpasand K, Farahani N, Meybodi TE, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24(1):58.","journal-title":"Mol Cancer"},{"issue":"5","key":"4315_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.cmet.2013.09.013","volume":"18","author":"K Masui","year":"2013","unstructured":"Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013;18(5):726\u201339.","journal-title":"Cell Metab"},{"issue":"6","key":"4315_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0124","volume":"1","author":"K Tanaka","year":"2011","unstructured":"Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, et al. Oncogenic EGFR signaling activates an mTORC2-NF-\u03baB pathway that promotes chemotherapy resistance. Cancer Discov. 2011;1(6):524\u201338.","journal-title":"Cancer Discov"},{"issue":"3","key":"4315_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.55730\/1300-0144.5828","volume":"54","author":"Z Yildirim","year":"2024","unstructured":"Yildirim Z, Do\u011fan E, G\u00fcler Kara H, Kosova B, Bozok V. STING activation increases the efficiency of temozolomide in PTEN harbouring glioblastoma cells. Turk J Med Sci. 2024;54(3):607\u201314.","journal-title":"Turk J Med Sci"},{"issue":"28","key":"4315_CR16","doi-asserted-by":"publisher","first-page":"e2111003119","DOI":"10.1073\/pnas.2111003119","volume":"119","author":"G Berger","year":"2022","unstructured":"Berger G, Knelson EH, Jimenez-Macias JL, Nowicki MO, Han S, Panagioti E, Lizotte PH, Adu-Berchie K, Stafford A, Dimitrakakis N, et al. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proc Natl Acad Sci U S A. 2022;119(28):e2111003119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4315_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17(1):31.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4315_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41417-025-00905-9","volume":"32","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, He H, Fu X, Liu G, Wang H, Zhong W, Xu X, Chen B, Mei L. Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances. Cancer Gene Ther. 2025;32(6):595\u2013607.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"4315_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","volume":"42","author":"W Wang","year":"2024","unstructured":"Wang W, Li T, Cheng Y, Li F, Qi S, Mao M, Wu J, Liu Q, Zhang X, Li X, et al. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Cancer Cell. 2024;42(5):815\u2013e832812.","journal-title":"Cancer Cell"},{"key":"4315_CR20","doi-asserted-by":"publisher","first-page":"122708","DOI":"10.1016\/j.biomaterials.2024.122708","volume":"311","author":"J Li","year":"2024","unstructured":"Li J, Yang J, Jiang S, Tian Y, Zhang Y, Xu L, Hu B, Shi H, Li Z, Ran G, et al. Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy. Biomaterials. 2024;311:122708.","journal-title":"Biomaterials"},{"key":"4315_CR21","doi-asserted-by":"crossref","unstructured":"Erices JI, Bizama C, Niechi I, Uribe D, Rosales A, Fabres K, Navarro-Mart\u00ednez G, Torres \u00c1, San Mart\u00edn R, Roa JC et al. Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets. Int J Mol Sci. 2023;24(8):7047.","DOI":"10.3390\/ijms24087047"},{"issue":"3","key":"4315_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486\u2013541.","journal-title":"Cell Death Differ"},{"issue":"2","key":"4315_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"4315_CR24","doi-asserted-by":"publisher","first-page":"101001","DOI":"10.1016\/j.gendis.2023.04.032","volume":"11","author":"S Yang","year":"2024","unstructured":"Yang S, Deng M, Xiong Y, Xiong B, Fu J, Wang J, Zhang J, Han G, Liu J, Tan Y. Development and validation of an immunogenic cell death-related prognostic model, and landscape of the tumor immune microenvironment in glioblastoma. Genes Dis. 2024;11(3):101001.","journal-title":"Genes Dis"},{"issue":"15","key":"4315_CR25","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/0008-5472.CAN-22-3382","volume":"83","author":"I Mondal","year":"2023","unstructured":"Mondal I, Das O, Sun R, Gao J, Yu B, Diaz A, Behnan J, Dubey A, Meng Z, Eskandar E, et al. PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma. Cancer Res. 2023;83(15):2527\u201342.","journal-title":"Cancer Res"},{"issue":"3","key":"4315_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/neuonc\/noy164","volume":"21","author":"M Korja","year":"2019","unstructured":"Korja M, Raj R, Sepp\u00e4 K, Luostarinen T, Malila N, Sepp\u00e4l\u00e4 M, M\u00e4enp\u00e4\u00e4 H, Pitk\u00e4niemi J. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol. 2019;21(3):370\u20139.","journal-title":"Neuro Oncol"},{"key":"4315_CR27","doi-asserted-by":"publisher","first-page":"217601","DOI":"10.1016\/j.canlet.2025.217601","volume":"617","author":"M Rana","year":"2025","unstructured":"Rana M, Liou KC, Thakur A, Nepali K, Liou JP. Advancing glioblastoma therapy: Learning from the past and innovations for the future. Cancer Lett. 2025;617:217601.","journal-title":"Cancer Lett"},{"key":"4315_CR28","doi-asserted-by":"publisher","first-page":"217666","DOI":"10.1016\/j.canlet.2025.217666","volume":"620","author":"M Maleszewska","year":"2025","unstructured":"Maleszewska M, Roura AJ, Dabrowski MJ, Draminski M, Wojtas B. Decoding glioblastoma\u2019s diversity: Are neurons part of the game? Cancer Lett. 2025;620:217666.","journal-title":"Cancer Lett"},{"key":"4315_CR29","doi-asserted-by":"publisher","first-page":"121690","DOI":"10.1016\/j.biomaterials.2022.121690","volume":"288","author":"G Zhong","year":"2022","unstructured":"Zhong G, Long H, Zhou T, Liu Y, Zhao J, Han J, Yang X, Yu Y, Chen F, Shi S. Blood-brain barrier Permeable nanoparticles for Alzheimer\u2019s disease treatment by selective mitophagy of microglia. Biomaterials. 2022;288:121690.","journal-title":"Biomaterials"},{"issue":"7","key":"4315_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41571-025-01020-2","volume":"22","author":"T Kisby","year":"2025","unstructured":"Kisby T, Borst GR, Coope DJ, Kostarelos K. Targeting the glioblastoma resection margin with locoregional nanotechnologies. Nat Rev Clin Oncol. 2025;22(7):517\u201337.","journal-title":"Nat Rev Clin Oncol"},{"key":"4315_CR31","doi-asserted-by":"publisher","first-page":"122694","DOI":"10.1016\/j.biomaterials.2024.122694","volume":"311","author":"H You","year":"2024","unstructured":"You H, Geng S, Li S, Imani M, Brambilla D, Sun T, Jiang C. Recent advances in biomimetic strategies for the immunotherapy of glioblastoma. Biomaterials. 2024;311:122694.","journal-title":"Biomaterials"},{"issue":"26","key":"4315_CR32","doi-asserted-by":"publisher","first-page":"10904","DOI":"10.1039\/D3NR01667F","volume":"15","author":"J Wang","year":"2023","unstructured":"Wang J, Liu Y, Liu F, Gan S, Roy S, Hasan I, Zhang B, Guo B. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy. Nanoscale. 2023;15(26):10904\u201338.","journal-title":"Nanoscale"},{"key":"4315_CR33","doi-asserted-by":"publisher","first-page":"101167","DOI":"10.1016\/j.mam.2022.101167","volume":"91","author":"MN Russo","year":"2023","unstructured":"Russo MN, Whaley LA, Norton ES, Zarco N, Guerrero-C\u00e1zares H. Extracellular vesicles in the glioblastoma microenvironment: A diagnostic and therapeutic perspective. Mol Aspects Med. 2023;91:101167.","journal-title":"Mol Aspects Med"},{"key":"4315_CR34","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.2147\/IJN.S444582","volume":"18","author":"J Tian","year":"2023","unstructured":"Tian J, Han Z, Song D, Peng Y, Xiong M, Chen Z, Duan S, Zhang L. Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications. Int J Nanomed. 2023;18:7923\u201340.","journal-title":"Int J Nanomed"},{"issue":"15","key":"4315_CR35","doi-asserted-by":"publisher","first-page":"e2110364","DOI":"10.1002\/adma.202110364","volume":"34","author":"T Wu","year":"2022","unstructured":"Wu T, Liu Y, Cao Y, Liu Z. Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma. Adv Mater. 2022;34(15):e2110364.","journal-title":"Adv Mater"},{"issue":"8","key":"4315_CR36","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","volume":"186","author":"R Kalluri","year":"2023","unstructured":"Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610\u201326.","journal-title":"Cell"},{"issue":"11","key":"4315_CR37","doi-asserted-by":"publisher","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","volume":"16","author":"R Tenchov","year":"2022","unstructured":"Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA. ExosomesNature\u2019s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics. ACS Nano. 2022;16(11):17802\u201346.","journal-title":"ACS Nano"},{"issue":"7","key":"4315_CR38","doi-asserted-by":"publisher","first-page":"e70123","DOI":"10.1002\/jev2.70123","volume":"14","author":"X Yue","year":"2025","unstructured":"Yue X, Cui J, Ren S, Zhang Y, Li Y, Cui H, Huard J, Robbins PD, Mu X. NK-Cell-Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy-Induced Senescent Osteosarcoma Cells. J Extracell Vesicles. 2025;14(7):e70123.","journal-title":"J Extracell Vesicles"},{"issue":"8000","key":"4315_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"key":"4315_CR40","doi-asserted-by":"publisher","first-page":"578713","DOI":"10.1016\/j.jneuroim.2025.578713","volume":"407","author":"H McLean","year":"2025","unstructured":"McLean H, Drill M, Sequeira R, Jayakrishnan PC, Jeffree RL, Hunn M, O\u2019Brien TJ, Hamilton J, Monif M. Harnessing the innate immune system for glioblastoma therapeutics. J Neuroimmunol. 2025;407:578713.","journal-title":"J Neuroimmunol"},{"key":"4315_CR41","doi-asserted-by":"publisher","first-page":"102943","DOI":"10.1016\/j.ctrv.2025.102943","volume":"137","author":"N Wu","year":"2025","unstructured":"Wu N, Yang N, Zhang S, Wu H, Fang X, Lin W, Zhang Y, Qi X, Gong Y. Chimeric antigen receptor NK cells for breast cancer immunotherapy. Cancer Treat Rev. 2025;137:102943.","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"4315_CR42","doi-asserted-by":"publisher","first-page":"e2418053","DOI":"10.1002\/adma.202418053","volume":"37","author":"H You","year":"2025","unstructured":"You H, Zhang S, Zhang Y, Chen Q, Wu Y, Zhou Z, Zhao Z, Su B, Li X, Guo Y, et al. Engineered Bacterial Outer Membrane Vesicles-Based Doxorubicin and CD47-siRNA Co-Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma. Adv Mater. 2025;37(15):e2418053.","journal-title":"Adv Mater"},{"issue":"4","key":"4315_CR43","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1021\/acsnano.4c14675","volume":"19","author":"G Kong","year":"2025","unstructured":"Kong G, Liu J, Wang J, Yu X, Li C, Deng M, Liu M, Wang S, Tang C, Xiong W, et al. Engineered Extracellular Vesicles Modified by Angiopep-2 Peptide Promote Targeted Repair of Spinal Cord Injury and Brain Inflammation. ACS Nano. 2025;19(4):4582\u2013600.","journal-title":"ACS Nano"},{"key":"4315_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2147\/IJN.S395246","volume":"18","author":"H Li","year":"2023","unstructured":"Li H, Ding Y, Huang J, Zhao Y, Chen W, Tang Q, An Y, Chen R, Hu C. Angiopep-2 Modified Exosomes Load Rifampicin with Potential for Treating Central Nervous System Tuberculosis. Int J Nanomed. 2023;18:489\u2013503.","journal-title":"Int J Nanomed"},{"issue":"8","key":"4315_CR45","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1039\/D1BM00020A","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Wu R, Li Y, Wang L, Zhou R, Li L, Xiang Y, Wu J, Xing L, Huang Y. Angiopep-2-functionalized nanoparticles enhance transport of protein drugs across intestinal epithelia by self-regulation of targeted receptors. Biomater Sci. 2021;9(8):2903\u201316.","journal-title":"Biomater Sci"},{"issue":"5","key":"4315_CR46","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1039\/C9BM01750J","volume":"8","author":"XX Shi","year":"2020","unstructured":"Shi XX, Miao WM, Pang DW, Wu JS, Tong QS, Li JX, Luo JQ, Li WY, Du JZ, Wang J. Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma. Biomater Sci. 2020;8(5):1290\u20137.","journal-title":"Biomater Sci"},{"issue":"8","key":"4315_CR47","doi-asserted-by":"publisher","first-page":"e12255","DOI":"10.1002\/jev2.12255","volume":"11","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Zhai Y, Hao Y, Wang Q, Han F, Zheng W, Hong J, Cui L, Jin W, Ma S, et al. Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides. J Extracell Vesicles. 2022;11(8):e12255.","journal-title":"J Extracell Vesicles"},{"issue":"7","key":"4315_CR48","doi-asserted-by":"publisher","first-page":"e70134","DOI":"10.1002\/jev2.70134","volume":"14","author":"Y Gong","year":"2025","unstructured":"Gong Y, Jin L, Duan L, Xiao J, Li Y, Wang H, Wang H, Lin W, Zhang Y, Gan X, et al. Extracellular Vesicles Derived From Streptococcus anginosus Aggravate Lupus Nephritis by Triggering TLR2-MyD88-NF-\u03baB Signalling in NK Cells. J Extracell Vesicles. 2025;14(7):e70134.","journal-title":"J Extracell Vesicles"},{"issue":"36","key":"4315_CR49","doi-asserted-by":"publisher","first-page":"13693","DOI":"10.1039\/C7NR04128D","volume":"9","author":"HD Roberts-Dalton","year":"2017","unstructured":"Roberts-Dalton HD, Cocks A, Falcon-Perez JM, Sayers EJ, Webber JP, Watson P, Clayton A, Jones AT. Fluorescence labelling of extracellular vesicles using a novel thiol-based strategy for quantitative analysis of cellular delivery and intracellular traffic. Nanoscale. 2017;9(36):13693\u2013706.","journal-title":"Nanoscale"},{"issue":"10","key":"4315_CR50","doi-asserted-by":"publisher","first-page":"e4615","DOI":"10.1002\/bmc.4615","volume":"33","author":"LR Michels","year":"2019","unstructured":"Michels LR, Fachel FNS, Azambuja JH, Gelsleichter NE, Braganhol E, Teixeira HF. HPLC-UV method for temozolomide determination in complex biological matrices: Application for in vitro, ex vivo and in vivo studies. Biomed Chromatogr. 2019;33(10):e4615.","journal-title":"Biomed Chromatogr"},{"issue":"Pt 2","key":"4315_CR51","doi-asserted-by":"publisher","first-page":"114403","DOI":"10.1016\/j.jconrel.2025.114403","volume":"388","author":"H Tigro","year":"2025","unstructured":"Tigro H, Mo\u00eblo C, Pelcman J, Paslawski W, Chen G, Poska H, Shimmo R, Svenningsson P, Kronqvist N, Johansson J. Bri2 BRICHOS, a molecular chaperone-like domain that can cross brain vascular endothelial cells and deliver proteins into neurons. J Control Release. 2025;388(Pt 2):114403.","journal-title":"J Control Release"},{"issue":"24","key":"4315_CR52","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1039\/D5LC00799B","volume":"25","author":"L Wu","year":"2025","unstructured":"Wu L, Lin B, Fan H, Li Y. Establishment of an ultrasound-responsive microfluidic chip BBB-glioblastoma model for studying sonodynamic therapy-enhanced nanodrug delivery. Lab Chip. 2025;25(24):6673\u201387.","journal-title":"Lab Chip"},{"issue":"2","key":"4315_CR53","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","volume":"72","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C, Labadie KP, Kohli K, Kenerson HL, Daniel SK, et al. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut. 2023;72(2):325\u201337.","journal-title":"Gut"},{"issue":"1","key":"4315_CR54","doi-asserted-by":"publisher","first-page":"108","DOI":"10.29337\/ijsp.148","volume":"25","author":"G Adegboyega","year":"2021","unstructured":"Adegboyega G, Kanmounye US, Petrinic T, Ozair A, Bandyopadhyay S, Kuri A, Zolo Y, Marks K, Ramjee S, Baticulon RE, et al. Global Landscape of Glioblastoma Multiforme Management in the Stupp Protocol Era: Systematic Review Protocol. Int J Surg Protoc. 2021;25(1):108\u201313.","journal-title":"Int J Surg Protoc"},{"issue":"20","key":"4315_CR55","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017;377(20):1954\u201363.","journal-title":"N Engl J Med"},{"issue":"7","key":"4315_CR56","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(24)00160-1","volume":"23","author":"A Salvalaggio","year":"2024","unstructured":"Salvalaggio A, Pini L, Bertoldo A, Corbetta M. Glioblastoma and brain connectivity: the need for a paradigm shift. Lancet Neurol. 2024;23(7):740\u20138.","journal-title":"Lancet Neurol"},{"key":"4315_CR57","doi-asserted-by":"publisher","first-page":"101656","DOI":"10.1016\/j.mtbio.2025.101656","volume":"32","author":"Z Han","year":"2025","unstructured":"Han Z, Huang H, Li B, Zhao R, Wang Q, Liu H, Xue H, Zhou W, Li G. Engineering exosome membrane disguised thermal responsive system for targeted drug delivery and controlled release across the blood-brain barrier. Mater Today Bio. 2025;32:101656.","journal-title":"Mater Today Bio"},{"key":"4315_CR58","doi-asserted-by":"publisher","first-page":"124552","DOI":"10.1016\/j.ijpharm.2024.124552","volume":"663","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Li J, Wang Y, Tang C, Zhou Y, Li J, Lu X, Wang Y, Ma T, Xu H, et al. Angiopep-2 conjugated biomimetic nano-delivery system loaded with resveratrol for the treatment of methamphetamine addiction. Int J Pharm. 2024;663:124552.","journal-title":"Int J Pharm"},{"issue":"Pt 2","key":"4315_CR59","doi-asserted-by":"publisher","first-page":"116588","DOI":"10.1016\/j.bcp.2024.116588","volume":"230","author":"Q Tang","year":"2024","unstructured":"Tang Q, Ren T, Bai P, Wang X, Zhao L, Zhong R, Sun G. Novel strategies to overcome chemoresistance in human glioblastoma. Biochem Pharmacol. 2024;230(Pt 2):116588.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4315_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11060-023-04357-9","volume":"164","author":"L Gurrieri","year":"2023","unstructured":"Gurrieri L, Mercatali L, Ibrahim T, Fausti V, Dall\u2019Agata M, Riva N, Ranallo N, Pasini G, Tazzari M, Foca F, et al. Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series. J Neurooncol. 2023;164(1):55\u201364.","journal-title":"J Neurooncol"},{"key":"4315_CR61","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/j.ebiom.2021.103453","volume":"69","author":"G Price","year":"2021","unstructured":"Price G, Bouras A, Hambardzumyan D, Hadjipanayis CG. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine. 2021;69:103453.","journal-title":"EBioMedicine"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04315-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04315-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04315-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:01:56Z","timestamp":1783648916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04315-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4315"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04315-3","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University (Nanchang, Jiangxi). All tissues were confirmed by neuropathological examination, and the study was conducted with appropriate patient consent in compliance with a protocol approved by the Institutional Review Board (O-Medical Research Ethics Review (2024) (NO.21)). Participants gave informed consent to participate in the study before taking part. All mice were housed in specific pathogen-free (SPF) facilities at the Model Animal Research Center of Nanfang Hospital, Southern Medical University. Experiments were performed under an animal protocol (IACUC-LAC-20240301-002) approved by the Institutional Animal Care and Use Committee of Nanfang Hospital, Southern Medical University, in accordance with guidelines from the National Institutes of Health (NIH) and institutional regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"632"}}